1. Imeglimin: Current Development and Future Potential in Type 2 Diabetes

   • Chigoziri Konkwo
   • Rachel J. Perry

   Leading Article 28 November 2020 Pages: 185 - 190

   

2. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer

   • Nityam Rathi
   • Taylor Ryan McFarland
   • Umang Swami

   Leading Article Open access 28 December 2020 Pages: 191 - 206

   

3. Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis: Differential Downstream Receptor Signalling and Clinical Profile Effects

   • Jerold Chun
   • Gavin Giovannoni
   • Samuel F. Hunter

   Review Article Open access 08 December 2020 Pages: 207 - 231

   

4. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia

   • George G. Zhanel
   • Christina Deng
   • James A. Karlowsky

   Review Article 28 November 2020 Pages: 233 - 256

   

5. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

   • Tony S. Mok
   • Ying Cheng
   • Yi-Long Wu

   Original Research Article Open access 17 December 2020 Pages: 257 - 266

   

6. Brigatinib: A Review in ALK-Inhibitor Naïve Advanced ALK-Positive NSCLC

   • Sheridan M. Hoy

   Adis Drug Evaluation 02 February 2021 Pages: 267 - 275

   

7. Lumasiran: First Approval

   • Lesley J. Scott
   • Susan J. Keam

   AdisInsight Report 06 January 2021 Pages: 277 - 282

   

8. Lonafarnib: First Approval

   • Sohita Dhillon

   AdisInsight Report Open access 15 February 2021 Pages: 283 - 289

   

9. Naxitamab: First Approval

   • Anthony Markham

   AdisInsight Report 22 February 2021 Pages: 291 - 296

   

10. Correction to: Filgotinib: First Approval

    • Sohita Dhillon
    • Susan J. Keam

    Correction Open access 02 February 2021 Pages: 297 - 297